Navigation Links
Orexigen Therapeutics Announces European Filing Strategy and Reports Business and Financial Results for the Second Quarter Ended June 30, 2013
Date:8/6/2013

strative expenses. As of June 30, 2013, Orexigen had $55.8 million in cash and cash equivalents and an additional $40.2 million in marketable securities, for a total of $96.0 million.

Product candidates: Contrave (32 mg naltrexone sustained-release (SR)/360 mg bupropion SR) for the treatment of obesity: In 2012, Orexigen screened more than 13,000 patients, enrolled more than 10,400 and ultimately completed recruitment of the Light Study with approximately 8,900 randomized patients. The primary objective of the double-blind, randomized, placebo-controlled Light Study, which Orexigen is conducting under a Special Protocol Assessment with the FDA (United States Food and Drug Administration), is to rule out excess cardiovascular risk in overweight and obese patients receiving Contrave. An interim analysis and NDA resubmission is planned once the independent Data Monitoring Committee (DMC) has determined that sufficient information has been gathered for the analysis that would include at least 87 adjudicated major adverse cardiovascular events (MACE). Orexigen enrolled into the Light Study a patient population that the company predicted would have an annualized MACE rate between 1% and 2%. Orexigen is preparing to be ready to conduct the interim analysis and resubmit the Contrave NDA in the remaining months of 2013. Orexigen has licensed North American commercial rights to Takeda Pharmaceuticals. Orexigen owns Contrave rights throughout the rest of the world and intends to license commercial rights outside North America.

Empatic™, a fixed dose combination of bupropion SR and zonisamide SR, for the treatment of obesity: In a series of discussions with the FDA on the continued development of Empatic, the FDA stated that Phase 3 data for Empatic may be sufficient to support submission of an NDA without data from a cardiovascular outcomes trial. The FDA indicated that as long as the placebo-subtracted changes in body weight, blood pressure
'/>"/>

SOURCE Orexigen Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Unigenes Potent, Anorexigenic Peptide, UGP281, Demonstrates Dramatic Dose Dependent Reductions in Food Intake with Subsequent Significant Body Weight Reduction in Preclinical Studies
2. Orexigen Therapeutics to Present at the Jefferies 2012 Global Healthcare Conference
3. Orexigen Therapeutics to Present at the JMP Securities Healthcare Conference
4. Orexigen Therapeutics Announces the Light Study is Enrolling Faster than Originally Projected
5. Orexigen Therapeutics Schedules August 7, 2012 Webcast Discussion of Financial Results for the Second Quarter Ended June 30, 2012
6. Orexigen Therapeutics Reports Financial Results for the Second Quarter Ended June 30, 2012
7. Orexigen Therapeutics Announces Presentations at Upcoming Investor Conferences
8. Orexigen Therapeutics announces continued rapid enrollment into the Light Study; enrollment now expected to close by year end 2012
9. Orexigen Therapeutics Reports Financial Results for the Third Quarter Ended September 30, 2012
10. Orexigen Therapeutics To Host Analyst Day Event on December 18, 2012
11. Orexigen Therapeutics to Present at Upcoming Investor Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... YORK , Jan. 15, 2014 ... market research report is available in ... Global Markets and Technologies for Advanced ... Routes of Administration ...
(Date:1/14/2014)... 2014  Luminex Corporation (Nasdaq: LMNX ) today announced ... of 2013 on Monday, February 3, 2014. A press release ... of trading. (Logo: http://photos.prnewswire.com/prnh/20100104/LUMINEXLOGO ) ... operating highlights and financial results for the fourth quarter and ...
(Date:1/14/2014)... 2014 /PRNewswire-iReach/ -- Acumed,s new SLIC Screw System - ... instrumentation to place and insert the screw accurately - ... (e.g. ligament) repair or reconstruction as it holds the ... (Photo: http://photos.prnewswire.com/prnh/20140114/MN45636 ) The SLIC ...
Breaking Medicine Technology:Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 16Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 2Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 3Acumed introduces the Scapho-Lunate Inter Carpal (SLIC) Screw System 2Acumed introduces the Scapho-Lunate Inter Carpal (SLIC) Screw System 3
... Sept. 15, 2011 AcelRx Pharmaceuticals, Inc. (Nasdaq: ... the development and commercialization of innovative therapies for the ... Richard King, President and Chief Executive Officer, will present ... over the coming weeks as follows: UBS ...
... NEW YORK, Sept. 15, 2011 Reportlinker.com ... is available in its catalogue: ... 2010-2014 http://www.reportlinker.com/p0240543/Global-Blood-Glucose-Test-Strips-Market-2010-2014.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=In_Vitro_Diagnostic ... Blood Glucose Test Strips market to grow ...
Cached Medicine Technology:AcelRx Pharmaceuticals to Present at Two Healthcare Investor Conferences in the Second Half of September 2Global Blood Glucose Test Strips Market 2010-2014 2
(Date:4/22/2014)... 15 percent of all lung cancers are small ... often develop resistance to chemotherapy. However, researchers at ... new insights into the mechanisms leading to this ... , Chemotherapies work primarily by mediating B-cell lymphoma ... regulating cell death. Depending on their function, this ...
(Date:4/22/2014)... The Association for Molecular Pathology (AMP) released a ... Diagnostics on recommendations for a molecular diagnostics ... of education. The report was prepared by the ... the AMP Training and Education Committee. "Our goal ... future medical laboratory scientists appropriately in order to ...
(Date:4/22/2014)... rabbits, Johns Hopkins scientists have found a way to ... the development of atherosclerosis, the main cause of heart ... among humans. The condition develops when fat builds inside ... and hardened, greatly reducing their ability to feed oxygen-rich ... In a series of experiments, described April 7 in ...
(Date:4/22/2014)... German . , ... their mode of action is complex: In low concentrations ... while at high concentrations they can cause "oxidative stress", ... redox signaling unfolds in single cells and organelles in ... jointly by the teams of LMU Professor Martin Kerschensteiner ...
(Date:4/22/2014)... in massive health care spending, a new RAND study ... to incentivize pharmaceutical companies and device makers to develop ... existing medical technologies and their use, a new study ... and medical devices get created in the first place. ... with as little loss of health as possible and ...
Breaking Medicine News(10 mins):Health News:Scientists pinpoint protein that could improve small cell lung cancer therapies 2Health News:AMP publishes curriculum recommendations for medical laboratory scientists 2Health News:Scientists alter fat metabolism in animals to prevent most common type of heart disease 2Health News:Scientists alter fat metabolism in animals to prevent most common type of heart disease 3Health News:Scientists alter fat metabolism in animals to prevent most common type of heart disease 4Health News:Neuroimaging: Live from inside the cell 2Health News:US medical innovation needs smarter incentives to cut health spending, study finds 2Health News:US medical innovation needs smarter incentives to cut health spending, study finds 3
... New Quads Have ... Bottles , ... April 15, 2010 -- Tahitian Noni International (TNI) announced its new bioactive ... the network marketing industry. The new Tahitian Noni 4-liter Quad is designed to be placed ...
... ... of court a Workers’ Compensation claim for the amount of $34,000.00. , ... New Bedford, MA (PRWEB) April, 15, 2010 -- The law firm ... $34,000.00., , , , ,The employee was injured while on the job while working as a ...
... ... to facilitate a speedy recovery from one of the world’s worst natural disasters. The monies ... the rebuilding of Haiti. MBMI hopes that this initiative will inspire others to do the ... Delray Beach, Florida ...
... poor management of related condition leaves many undiagnosed, , ... Britain often fail to detect cases of chlamydia in ... British researchers contend. , They say that many urologists ... condition known as epididymo-orchitis, which causes inflammation of the ...
... well for golden years, study finds , THURSDAY, April 15 ... of old age is taking pleasure in your grandchildren, but ... social life, being married and having a partner who is ... of life, but having children or grandchildren matters little, the ...
... procedures will help save lives long-term , THURSDAY, April 15 ... nearing a "state of crisis" and needs to be repaired ... a new government report. , The authors of the ... conducted by the Institute of Medicine (IOM), calls for a ...
Cached Medicine News:Health News:Quad - The First 4-Liter Refrigerator Dispenser Introduced by Tahitian Noni International 2Health News:MBMI Steel Buildings is Saving Haiti One Building at a Time 2Health News:Friends, Not Grandkids, Key to Happy Retirement 2Health News:Friends, Not Grandkids, Key to Happy Retirement 3Health News:Experts Urge Fixes for Clinical Trials System in 'Crisis' 2Health News:Experts Urge Fixes for Clinical Trials System in 'Crisis' 3Health News:Experts Urge Fixes for Clinical Trials System in 'Crisis' 4
... Bulb Direct has been selling ... since 1996, and we are ... satisfaction guarantee. Check out our ... see our discount light bulbs ...
... Bulb Direct has been ... Internet since 1996, and we ... 100% satisfaction guarantee. Check out ... and see our discount light ...
... Bulb Direct has been selling ... since 1996, and we are ... satisfaction guarantee. Check out our ... see our discount light bulbs ...
... has been selling replacement bulbs ... and we are extremely proud ... Check out our catalog of ... discount light bulbs specials. ...
Medicine Products: